The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
sorry systemzero I have used the wrong terminology
"the Fast track option is part of the Technology appraisals track (single, multiple or fast track). Genedrive are in the Diagnostics assessment track – it doesn’t have the Fast track."
Anna at Wallbrook
Sorry for confusion.
Just the other side of the coin to your endless rubbish roger
you could all give it a rest and this board maybe just maybe, might become a useful source of information again.
unfortunately I doubt that will happen
Llyod
As far as I am aware there are IIs they are just holding less than the required amount to declare.
Quiet happy to be proved wrong but am pretty sure this is the case.
The chance of D Budd being removed by Share holders is small.
It isn't just about the money Guy it is also about the clinical value
the test will literally stop some children from losing their hearing this has value in future costs to NHS but far more importantly is the benefits to quality of life of those children.
What I am trying to say is that the nice result will not be all about the money. but that the money side makes sense (it isn't stupidly expensive.)
To me the biggest indicator is that fact that the NHS co-developed the test. So they saw the need and put time and resources into making it happen.
The biggest win if/when it is on the best practice guide lines is that it is then proof of concept and the next test is easier to sell and that makes the next test easier ect ect. It sort of snowballs.
if your seriously in trouble because of an investment you made, then you shouldn't of made it.
Sorry don't want to be harsh but the old adage "don't invest what you can't afford to lose" springs to mind. Particularly in a sector most of you had not idea about before jumping in with both feet.
As far as I know without further review, the Fast track option is part of the Technology appraisals track (single, multiple or fast track). Genedrive are in the Diagnostics assessment track – it doesn’t have the Fast track.
NICE manages the DAP process on behalf of the Department of Health and Social Care. NICE can only begin to appraise a technology when it has been formally referred by the Secretary of State for Health. It isn’t Company initiated. Most topics are identified by the National Institute for Health Research Innovation Observatory at the University of Newcastle. This centre notifies NICE about key new and emerging healthcare technologies that might be suitable for NICE technology appraisal.
thanks to Anna@ Walbrook :)